Puma Biotechnology
PBYI
112 hedge funds and large institutions have $89.7M invested in Puma Biotechnology in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 21 reducing their positions, and 15 closing their positions.
756% more call options, than puts
Call options by funds: $137K | Put options by funds: $16K
119% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 21
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
18% more capital invested
Capital invested by funds: $75.9M → $89.7M (+$13.8M)
12% more funds holding
Funds holding: 100 → 112 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.76% less ownership
Funds ownership: 60.63% → 59.88% (-0.76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$629K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$497K |
| 3 |
D.E. Shaw & Co
New York
|
+$481K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$444K |
| 5 |
Two Sigma Investments
New York
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$7.81M |
| 2 |
Millennium Management
New York
|
-$2.87M |
| 3 |
EP
Eversept Partners
New York
|
-$865K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$788K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$638K |
PBYI Hedge Fund Activity: Q4 2024 in Review
112 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2024, worth a combined $89.7M — up 18% from $75.9M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PBYI positions and 15 closed out — a net gain of 13 holders — while 46 added to existing stakes and 21 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $629K. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $7.81M sold.
- 112 institutional investors held Puma Biotechnology (PBYI) as of Q4 2024, up from 100 in Q3 2024.
- Funds reported $89.7M of Puma Biotechnology stock for Q4 2024, up 18% quarter-over-quarter.
- 28 funds opened new Puma Biotechnology positions in Q4 2024 and 15 closed out, a net change of +13 holders.
- The largest Puma Biotechnology buyer in Q4 2024 was Kennedy Capital Management, an estimated $629K added.
- The largest Puma Biotechnology seller in Q4 2024 was Frazier Life Sciences Management, an estimated $7.81M sold.
Based on aggregated 13F filings for Q4 2024.